中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    Viral Diseases NASH/PBC Cancer Exploratory Indications
  • Products&Pipeline
    Pipeline Products Clinical Trials
  • Partnership
  • Investors
    Financials & Filing Presentation Materials
  • News
  • Careers
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • Ascletis Accredited as “One of China’s Top Ten Innovative Companies in 2019”

    2019-12-07

  • Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout

    2019-11-29

  • Ascletis to Present at the 17th Annual Morgan Stanley Asia Pacific Summit

    2019-11-26

  • Dr. Jinzi Wu was Selected as the 10th Science and Technology New Zhejiang Merchants

    2019-11-08

  • Manuscript Publication of the First All-oral DAA HCV Regimen Developed by Ascletis from China in the Journal of Clinical and Translational Hepatology

    2019-10-21

  • Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer

    2019-10-08

  • Dr. Jinzi J. Wu to Attend The Fortune Global Sustainability Forum 2019

    2019-09-04

  • Ascletis Received IND Approval for its NASH Drug

    2019-08-28

  • Ascletis Opens Clinical Development Shanghai Center

    2019-08-12

  • Ascletis’ Strategic Partner 3-V Biosciences Announced its Name Change and Financing Status

    2019-08-06

 
  • 1
  • 2
  • 3
  •  
  • »
    • © 2018 Ascletis Pharma Inc.
    • 浙公网安备 33010802003344号
    • All Rights Reserved
    • 浙ICP备 11050387号-1

    contact

    • pr@ascletis.com
    • bd@ascletis.com
    • hr@ascletis.com
    • clinicaltrials@ascletis.com

    © 2018 Ascletis Pharma Inc. All Rights Reserved
    浙公网安备 33010802003344号 浙ICP备11050387号-1